Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics Q2 2024 Earnings Report

MoonLake Immunotherapeutics logo
$52.92 +2.48 (+4.92%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$53.00 +0.08 (+0.15%)
As of 08/1/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.11
One Year Ago EPS
-$0.23

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MoonLake Immunotherapeutics' Q1 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MoonLake Immunotherapeutics Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile

More Earnings Resources from MarketBeat